Kazia Therapeutics
KZIA
8 hedge funds and large institutions have $723K invested in Kazia Therapeutics in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
53% more capital invested
Capital invested by funds: $472K → $723K (+$251K)
0.37% more ownership
Funds ownership: 6.14% → 6.51% (+0.37%)
0% more funds holding
Funds holding: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$92.9K |
| 2 |
Morgan Stanley
New York
|
+$74.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$25K |
KZIA Hedge Fund Activity: Q2 2020 in Review
8 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2020, worth a combined $723K — up 53% from $472K a quarter earlier.
Fund positioning in KZIA was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $92.9K. The largest seller was UBS Group, cutting an estimated $25K.
- 8 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $723K of Kazia Therapeutics stock for Q2 2020, up 53% quarter-over-quarter.
- 0 funds opened new Kazia Therapeutics positions in Q2 2020 and 0 closed out.
- The largest Kazia Therapeutics buyer in Q2 2020 was Renaissance Technologies, an estimated $92.9K added.
- The largest Kazia Therapeutics seller in Q2 2020 was UBS Group, an estimated $25K sold.
Based on aggregated 13F filings for Q2 2020.